Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Prochieve maker provides Q3 report, updates PROTERM study
December 12th, 2004
Columbia Laboratories, Inc., (CBRX) announced financial results for the third quarter and 9 months ended September 30, 2004. Highlights of the quarter included: 1) Net sales of $5.1 million, a 9.2% increase from second-quarter 2004 levels. 2) Loss per share improved to $0.14 from a loss of $0.16 in second-quarter 2004. 3) Positive data from a pilot study of Prochieve 8% (progesterone gel) suggested use of Prochieve 8% and estradiol with clomiphene citrate more than doubled pregnancy rates versus clomiphene citrate alone. 4) Positive results of a phase III study of Striant (testosterone...
Source: Medical Letter on the CDC & FDA (2004-12-12)
|
